DBVT.F logo

DBV Technologies OTCPK:DBVT.F Stock Report

Last Price

US$2.80

Market Cap

US$472.6m

7D

0%

1Y

n/a

Updated

03 Aug, 2022

Data

Company Financials +

DBV Technologies S.A.

OTCPK:DBVT.F Stock Report

Market Cap: US$472.6m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

DBV Technologies S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for DBV Technologies
Historical stock prices
Current Share Price€2.80
52 Week High€2.80
52 Week Low€2.80
Beta1.56
1 Month Change0%
3 Month Changen/a
1 Year Changen/a
3 Year Changen/a
5 Year Change-96.59%
Change since IPO-90.93%

Recent News & Updates

Recent updates

Shareholder Returns

DBVT.FUS BiotechsUS Market
7D0%-1.3%-0.08%
1Yn/a10.6%27.7%

Return vs Industry: Insufficient data to determine how DBVT.F performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how DBVT.F performed against the US Market.

Price Volatility

Is DBVT.F's price volatile compared to industry and market?
DBVT.F volatility
DBVT.F Average Weekly Movementn/a
Biotechs Industry Average Movement11.8%
Market Average Movement6.0%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: DBVT.F has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine DBVT.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200288Daniel Tasséhttps://www.dbv-technologies.com

DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The milk-induced company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow’s milk protein allergy (CMPA); Viaskin Egg, a pre-clinical stage product for the treatment of hen’s egg allergy; and booster vaccine for Bordetella pertussis.

DBV Technologies S.A. Fundamentals Summary

How do DBV Technologies's earnings and revenue compare to its market cap?
DBVT.F fundamental statistics
Market capUS$472.59m
Earnings (TTM)-US$77.45m
Revenue (TTM)US$8.33m

56.7x

P/S Ratio

-6.1x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DBVT.F income statement (TTM)
RevenueUS$8.33m
Cost of RevenueUS$0
Gross ProfitUS$8.33m
Other ExpensesUS$85.78m
Earnings-US$77.45m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Nov 03, 2022

Earnings per share (EPS)-0.82
Gross Margin100.00%
Net Profit Margin-929.91%
Debt/Equity Ratio0.4%

How did DBVT.F perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.